{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T10:26:35Z","timestamp":1768731995410,"version":"3.49.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2000,8,1]],"date-time":"2000-08-01T00:00:00Z","timestamp":965088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Daily administration of parathyroid hormone (PTH) and PTH-related protein (PTHrP) peptides has been shown to increase bone mass and strength in animals and, for PTH, to increase bone mass in humans. Long-term direct comparison of multiple members of the PTH\/PTHrP family in vivo has not been reported. We therefore selected three PTH\/PTHrP molecules for direct comparison in vivo in an adult rat model of postmenopausal osteoporosis: PTH(1-34), PTHrP(1-36), and the PTH analog, SDZ-PTH 893 {Leu8, Asp10, Lys11, Ala16, Gln18, Thr33, Ala34 human PTH 1\u201334 [hPTH(1-34)]}. A 6-month study was performed in which adult (6-month-old) vehicle-treated ovariectomized (OVX) and sham OVX rats were compared with OVX rats receiving 40 \u03bcg\/kg per day of either PTH(1-34), PTHrP(1-36), or PTH-SDZ-893. Bone mass, as assessed by ash weight and densitometry, bone histomorphometry, biomechanical properties at trabecular and cortical sites, and indices of bone formation markedly increased in all three PTH\/PTHrP peptide-treated groups as compared with controls. In general, this improvement followed a rank order of SDZ-PTH-893 &amp;gt; PTH &amp;gt; PTHrP. The adverse effect profile also was greatest with SDZ-PTH-893; these rats developed moderate hypercalcemia, marked renal calcium accumulation, and displayed a 13% mortality. These studies show that PTH(1-34), PTHrP(1-36), and PTH-SDZ-893 significantly and progressively increase bone mass and bone strength in this rat model of postmenopausal osteoporosis. The adverse effect profile correlates in general terms with efficacy. All three peptides show promise as skeletal anabolic agents. Further studies in humans will be required to define optimal efficacy-to-adverse effect ratios and relative efficacy for each peptide in human osteoporosis.<\/jats:p>","DOI":"10.1359\/jbmr.2000.15.8.1517","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T03:20:21Z","timestamp":1146108021000},"page":"1517-1525","source":"Crossref","is-referenced-by-count":117,"title":["Six-Month Daily Administration of Parathyroid Hormone and Parathyroid Hormone\u2014Related Protein Peptides to Adult Ovariectomized Rats Markedly Enhances Bone Mass and Biomechanical Properties: A Comparison of Human Parathyroid Hormone 1\u201334, Parathyroid Hormone-Related Protein 1\u201336, and SDZ-Parathyroid Hormone 893"],"prefix":"10.1093","volume":"15","author":[{"given":"A. F.","family":"Stewart","sequence":"first","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. L.","family":"Cain","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, Indiana, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. B.","family":"Burr","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, Indiana, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Jacob","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, Indiana, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. H.","family":"Turner","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, Indiana, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Hock","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, Indiana, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc K.","family":"Drezner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2024020714093333300_bib1","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199412153312404","article-title":"Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency","volume":"331","author":"Finkelstein","year":"1994","journal-title":"N Engl J Med"},{"key":"2024020714093333300_bib2","first-page":"1214","article-title":"Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotrophin-releasing hormone analog administration in women with endometriosis","volume":"84","author":"Finkelstein","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020714093333300_bib3","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised clinical trial of the effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"issue":"Suppl","key":"2024020714093333300_bib4","first-page":"1109","article-title":"A randomised clinical trial of the 1\u201384 hPTH for treatment of postmenopausal osteoporosis","volume":"23","author":"Lindsay","year":"1998","journal-title":"Bone"},{"key":"2024020714093333300_bib5","first-page":"620","article-title":"A randomized controlled clinical trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis","volume":"82","author":"Hodsman","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020714093333300_bib6","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI3914","article-title":"Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis","volume":"102","author":"Lane","year":"1998","journal-title":"J Clin Invest"},{"key":"2024020714093333300_bib7","first-page":"59","author":"Roe","year":"1999"},{"key":"2024020714093333300_bib8","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/jbmr.5650110404","article-title":"PTH: A future role in the management of osteoporosis?","volume":"11","author":"Reeve","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024020714093333300_bib9","first-page":"690","article-title":"Anabolic actions of parathyroid hormone on bone","volume":"14","author":"Dempster","year":"1993","journal-title":"Endocr Rev"},{"key":"2024020714093333300_bib10","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1210\/endo.138.10.5440","article-title":"Biosynthetic human PTH(1-34) effects on bone quality in aged ovariectomized rats","volume":"138","author":"Sato","year":"1997","journal-title":"Endocrinology"},{"key":"2024020714093333300_bib11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/jbmr.5650110402","article-title":"Temporal expression of the anabolic action of PTH in cancellous bone of ovariectiomized rats","volume":"11","author":"Meng","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024020714093333300_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jbmr.5650070110","article-title":"Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone","volume":"7","author":"Hock","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2024020714093333300_bib13","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1172\/JCI119491","article-title":"Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells","volume":"99","author":"Ishizuya","year":"1997","journal-title":"J Clin Invest"},{"key":"2024020714093333300_bib14","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1359\/jbmr.1999.14.4.536","article-title":"Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY 333334, on remodeling and mechanical properties of cortical bone in rabbits","volume":"14","author":"Hirano","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2024020714093333300_bib15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1359\/jbmr.1999.14.2.163","article-title":"Comparison of recombinant human PTH(1-34) (LY 333334) with a C-terminally substituted analog of human PTH-related protein (1-34) (RS 66271): In vitro activity and in vivo pharmacologic effects in rats","volume":"14","author":"Frolick","year":"1999","journal-title":"J Bone Miner Res"},{"issue":"Suppl","key":"2024020714093333300_bib16","first-page":"S317","article-title":"SDZ-PTS 893: Pharmacological profile of a highly potent novel PTH analog","volume":"12","author":"Gamse","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2024020714093333300_bib17","first-page":"347","volume-title":"Principles of Bone Biology","author":"Yang","year":"1996"},{"key":"2024020714093333300_bib18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1152\/physrev.1996.76.1.127","article-title":"Defining the physiologic roles of parathyroid hormone-related protein in normal physiology","volume":"76","author":"Philbrick","year":"1996","journal-title":"Physiol Rev"},{"key":"2024020714093333300_bib19","first-page":"199","article-title":"Parathyroid hormone-related protein(1-36) is equipotent with parathyroid hormone(1-34) in humans","volume":"81","author":"Everhart-Caye","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020714093333300_bib20","first-page":"900","article-title":"Parathyroid hormone-related protein(1-36) is biologically active when administered subcutaneously to humans","volume":"82","author":"Henry","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020714093333300_bib21","first-page":"60","article-title":"Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans","volume":"80","author":"Fraher","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020714093333300_bib22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S8756-3282(96)00221-9","article-title":"PTHrP(1-36) as a therapeutic anabolic agent for the treatment of osteoporosis","volume":"19","author":"Stewart","year":"1996","journal-title":"Bone"},{"key":"2024020714093333300_bib23","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1210\/endo-125-4-2022","article-title":"Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) 1\u201334 and PTH 1\u201334 on bone in rats","volume":"125","author":"Hock","year":"1989","journal-title":"Endocrinology"},{"key":"2024020714093333300_bib24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/BF00296214","article-title":"Synthetic parathyroid hormone-like protein (1-74) is anabolic for bone in vivo","volume":"51","author":"Weir","year":"1992","journal-title":"Calcif Tissue Int"},{"key":"2024020714093333300_bib25","first-page":"2786","article-title":"Dissociation of bone formation from resorption during two-week treatment with hPTHrP(1-36) in humans: Potential as an anabolic therapy for osteoporosis","volume":"83","author":"Plotkin","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020714093333300_bib26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: Standardization of nomenclature, symbols and units","volume":"2","author":"Parfitt","year":"1987","journal-title":"J Bone Miner Res"},{"key":"2024020714093333300_bib27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/8756-3282(93)90081-K","article-title":"Basic biomechanical measures in bone: A tutorial","volume":"14","author":"Turner","year":"1993","journal-title":"Bone"},{"key":"2024020714093333300_bib28","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1210\/endo.139.11.6307","article-title":"LY35381 HCl: An improved raloxifene analog with bone efficacy complimentary to PTH(1-34)","volume":"139","author":"Sato","year":"1998","journal-title":"Endocrinology"},{"key":"2024020714093333300_bib29","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effect of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women","volume":"337","author":"Delmas","year":"1997","journal-title":"N Engl J Med"},{"key":"2024020714093333300_bib30","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jama.1996.03540170033029","article-title":"The effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen\/progestin interventions (PEPI) trial","volume":"276","author":"The writing group for the PEPI trial","year":"1996","journal-title":"JAMA"},{"key":"2024020714093333300_bib31","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"2024020714093333300_bib32","first-page":"1535","article-title":"Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): Kinetics and biochemical response in estrogenized osteoporotic patients","volume":"77","author":"Lindsay","year":"1993","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.2000.15.8.1517","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/15\/8\/1517\/56603312\/5650150811.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/15\/8\/1517\/56603312\/5650150811.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:01:03Z","timestamp":1710342063000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/15\/8\/1517-1525\/7515363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8,1]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[2000,8,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.2000.15.8.1517","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2000,8,1]]},"published":{"date-parts":[[2000,8,1]]}}}